Merck and Co Inc/ US58933Y1055 /
2024-07-31 9:30:51 PM | Chg. -2.92 | Volume | Bid9:30:51 PM | Ask9:30:51 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
112.33USD | -2.53% | 15.98 mill. Turnover: 1.46 bill. |
112.32Bid Size: 600 | 112.34Ask Size: 300 | 286.27 bill.USD | 2.62% | 807.32 |
GlobeNewswire
06-11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06-06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
05-28
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
05-23
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
05-16
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-14
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
05-08
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
04-24
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
04-15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness